Evidence map›Paper›PMID 38918997›Full record

ReviewPharmaceutical nanotechnology2025

A Comprehensive Review of Nanomaterials as Potential Weapons against Multidrug-resistant

Bhargav Devliya, Bimalkumar Patel, Shreya J Chauhan, Hitesh D Patel

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Pharmaceutical nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Bhargav DevliyaDepartment of Chemistry, School of Sciences, Gujarat University, Ahmedabad, India.
Bimalkumar PatelDepartment of Chemistry, School of Sciences, Gujarat University, Ahmedabad, India.
Shreya J ChauhanDepartment of Environmental Science, School of Sciences, Gujarat University, Ahmedabad, India.
Hitesh D PatelDepartment of Chemistry, School of Sciences, Gujarat University, Ahmedabad, India.

Funding

SHODH- ScHeme of Developing High- Quality Research fellowship 2022013896Wellcome Trust 220066
6 · The paper itself

Abstract

Multidrug-resistant Staphylococcus aureus is a serious public health problem with high fatality rates and difficult treatment. Conventional antimicrobials are limited in their effectiveness against MRSA due to developing resistance mechanisms and protective biofilms. Nanomaterials present a potential alternative since they offer targeted drug delivery and synergetic effects of nanoconjugates, eradicate biofilms, and use photothermal and photodynamic therapies. Furthermore, the discovery of nanovaccines holds the potential for enhancing immune responses against multidrugresistant S. aureus. Nanoparticles show considerable promise in the battle against multidrugresistant S. aureus, but significant obstacles remain, including determining their possible toxicity, scalability, and cost-effectiveness for widespread clinical application. However, by overcoming these barriers, nanomaterial-based techniques provide a viable route for tackling multidrug resistance in S. aureus, opening the path for a future in which successful therapies are within reach.

Indexed as

Anti-Bacterial AgentsDrug Resistance, Multiple, BacterialMethicillin-Resistant Staphylococcus aureusNanostructuresStaphylococcal InfectionsAnimalsBiofilmsDrug Delivery SystemsHumansAnti-Bacterial AgentsAntimicrobial resistancediagnosticsnanobiosensorsnanoconjugatesphotodynamic therapies.S. aureus

Identifiers

PMID38918997

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.